Disclosed are a diphenylaminopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotope derivatives thereof, a pharmaceutical composition comprising these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and can be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.